ReviewNature reviews. Nephrology2021
Kidney injury and disease in patients with haematological malignancies.
Review in Nature reviews. Nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Drowning the kidneys: from fluid overload to physiology-guided fluid management in onco-hematology.Clinical kidney journal · 2026Review
- Ten tips for kidney biopsy in cancer patients.Clinical kidney journal · 2026Review
- Renal Involvement in Indolent and Aggressive B-Cell Neoplasms: A Comparative Study of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Diffuse Large B-Cell Lymphoma.Current oncology (Toronto, Ont.) · 2026Article
- Acute Renal Failure Revealing Primary Renal Lymphoma With Bone Involvement: A Rare Case.Cureus · 2026Article
- Acute kidney injury in immunocompromised patients with acute respiratory failure: insights from the HIGH clinical trial and relation with mechanical ventilation.Annals of intensive care · 2026Article
- Renal interstitial infiltration by non-Hodgkin lymphoma: clinicopathological features, outcomes, and prognostic markers from a Chinese biopsy cohort.Renal failure · 2025Article
- Acute kidney injury: pathogenesis and therapeutic interventions.Molecular biomedicine · 2025Review
- Navigating the Complexities of Cancer Treatment-Induced Hypertension.Journal of cardiovascular development and disease · 2025Review
- An Unusual Case of Essential Thrombocythemia and Acute Kidney Injury: Case Report and Literature Review.Diseases (Basel, Switzerland) · 2025Article
- Correlation between β2-microglobulin level and risk of cardiovascular events and prognosis in hemodialysis patients.American journal of translational research · 2025Article
- [Clinical efficacy and safety of liposomal amphotericin B in the salvage treatment of invasive fungal disease in patients with hematological diseases].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Article
- Acute kidney injury in critical care: complications of hemophagocytic lymphohistiocytosis.Frontiers in immunology · 2024Review
- Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies.OncoTargets and therapy · 2024Review
- Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease.Kidney international reports · 2023Article
- Primary renal lymphoma presenting as renal failure: A case report and review of literature from 1989.World journal of clinical cases · 2023Article
- Do outcomes for patients with hospital-acquired Acute Kidney Injury (H-AKI) vary across specialties in England?BMC nephrology · 2023Observational
- Is MG53 a potential therapeutic target for cancer?Frontiers in endocrinology · 2023Review
- Review
- Acute kidney injury due to thrombotic microangiopathy in a patient with primary Sjögren's syndrome.Renal failure · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 3 countries.
Funding
Abstract
Acute kidney injury (AKI) is common in patients with cancer, especially in those with haematological malignancies. Kidney injury might be a direct consequence of the underlying haematological condition. For example, in the case of lymphoma infiltration or extramedullary haematopoiesis, it might be caused by a tumour product; in the case of cast nephropathy it might be due to the presence of monoclonal immunoglobulin; or it might result from tumour complications, such as hypercalcaemia. Kidney injury might also be caused by cancer treatment, as many chemotherapeutic agents are nephrotoxic. High-intensity treatments, such as high-dose chemotherapy followed by haematopoietic stem cell transplantation, not only increase the risk of infection but can also cause AKI through various mechanisms, including viral nephropathies, engraftment syndrome and sinusoidal obstruction syndrome. Some conditions, such as thrombotic microangiopathy, might also result directly from the haematological condition or the treatment. Novel immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor T cell therapy, can also be nephrotoxic. As new therapies for haematological malignancies with increased anti-tumour efficacy and reduced toxicity are developed, the number of patients receiving these treatments will increase. Clinicians must gain a good understanding of the different mechanisms of kidney injury associated with cancer to better care for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.